Immunosuppression and modulation in liver transplantation

Nephrology Dialysis Transplantation

Volumn 19, Issue SUPPL. 4, 2004, Pages

  Encke, Jens ^a   Uhl, Waldemar ^a   Stremmel, Wolfgang ^a   Sauer, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antiproliferative agents; Calcineurin inhibitors; Corticosteroids; Immunosuppression; Liver transplantation; Living related liver transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOPLASMIC RECEPTOR; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL CRAMP; ACUTE GRAFT REJECTION; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CATARACT; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CUSHING SYNDROME; DIABETES MELLITUS; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DUODENUM ULCER; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HEADACHE; HEPATITIS B; HEPATITIS C; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER TRANSPLANTATION; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; ORGAN DONOR; OSTEOPOROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; STOMACH ULCER; SURVIVAL RATE; TREMOR;

AZATHIOPRINE; CALCINEURIN; GLUCOCORTICOIDS; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS;

EID: 4344672577     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1037     Document Type: Review

References (27)

1. Levy GA. Long-term immunosuppression and drug interactions. Liver Transplant 2001; 7: S53-S59
2. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083-1091
3. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1115
4. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360: 1119-1125
5. Cosimi AB, Jenkins RL, Rohrer RJ, Delmonico FL, Hoffman M, Monaco AP. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990; 125: 781-784; discussion, 785
6. Wall WJ, Ghent CN, Roy A, McAlister VC, Grant DR, Adams PC. Use of OKT3 monoclonal antibody as induction therapy for control of rejection in liver transplantation. Dig Dis Sci 1995; 40: 52-7
7. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663
8. Adams DH, Neuberger JM. Patterns of graft rejection following liver transplantation. J Hepatol 1990; 10: 113-119
9. Adams DH, Neuberger JM. Treatment of acute rejection. Semin Liver Dis 1992; 12: 80-88
10. Greig P, Lilly L, Scudamore C et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transplant 2003; 9: 587-595
11. Everson GT. Impact of immuno suppressive therapy on recurrence of hepatitis C. Liver Transplant 2002; 8: S19-S27
12. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-38
13. Bennett WM, DeMattos A, Meyer MM andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-100
14. Campbell SB, Johnson DW. Patient management by cyclosporine C2 monitoring: not enough science yet to justify the practice. Transplantation 2003; 75: 1917-1918
15. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-428
16. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983
17. Wiesner R, Rabkin J, Klintmalin G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transplant 2001; 7: 442-450
18. Manzarbeitia C, Reich DJ, Rothstein KD, Braitman LE, Levin S, Munoz SJ. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transplant 2001; 7: 93-99
19. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999; 68: 155-157
20. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042
21. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transplant 2003; 9: 126-129
22. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-1717
23. Gibbs JF, Husberg BS, Klintmalm GB et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. Transplant Proc 1993; 25: 622-623
24. Demetris AJ, Fung JJ, Todo S et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy - a clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056-1062
25. Hebert MF, Ascher NL, Lake JR et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67: 707-712
26. Chen CL, Fan ST, Lee SG, Makuuchi M, Tanaka K. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation 2003; 75: S6-S11
27. Lo CM. Complications and long-term outcome of living liver donors: a survey of 1508 cases in five Asian centers. Transplantation 2003; 75: S12-S15